乳腺癌及癌周组织中淋巴内皮生长因子及其受体的表达和意义

On expression of VEGF-C and its receptor in breast carcinoma tissue and in peritumoral tissue and their clinic significance

目的研究淋巴内皮生长因子(VEGF-C)及其受体3(VEGFR3)在乳腺癌组织及癌周组织中的表达和临床意义。方法采用免疫组织化学SP法检测70例患者乳腺癌组织及其癌周组织中淋巴VEGF-C及其VEGFR3的表达情况。结果VEGF-C在乳腺癌组织中阳性表达率为78.6%,在癌周组织中为54.3%,两组比较差异有统计学意义(P<0.01)。VEGFR3阳性的脉管数在乳腺癌组织中为7.896±5.565,癌周组织中为10.306±6.518,两者比较差异有统计学意义(P<0.01)。VEGFR3与VEGF-C表达具有明显的相关性(r=0.66,P<0.05)。VEGF-C在乳腺癌微转移阳性组为87.5%,在阴性组为71.1%,两组比较差异有统计学意义(P<0.01)。VEGFR3在淋巴转移阳性组为12.484±6.505,阴性组为8.471±6.017,两组比较差异有统计学意义(P<0.01)。结论VEGF-C主要表达于乳腺癌组织肿瘤细胞中,而VEGFR3则表达于乳腺癌间质和癌周组织的淋巴管内皮细胞;VEGF-C在乳腺癌组织的表达及其受体在癌周组织的表达与乳腺癌淋巴结的微转移密切相关。

Objective To study the expression of VEGF-C and its receptor in breast carcinoma tissue and in peritumoral tissue,as well as their clinic significance.Methods Immunohistochemistry SP method was used to examine the expression of VEGF-C and VEGFR3 in 70 cases of breast cancer and in its peritu- moral tissue.Results In all 70 cases of breast cancer,the positive expression rate of VEGF-C in breast car- cinoma tissue was 78.6 %,and its rate in peritumoral tissue was 54.3 %.There was a significant stastistic dif- ference between the two groups(P<0.01).The positive lymph vessel of VEGFR3 was higher in peritumoral tis- sue(10.306±6.158)than that in breast carcinoma tissue(7.896±5.565)(P<0.01).The expression of VEGFR3 was closely correlated with VEGF-C expression(r=0.66,P<0.05).The positive expression rate of VEGF-C in lymph node metastasis group was 87.5 %,and in no lymph node metastasis group was 71.1%(P<0.01). The VEGFR3 positive vessels in lymph node metastasis group(12.484±6.505)was significantly higher than in non-lymph node metastasis group(8.471±6.017)(P<0.01).Conclusion The positive expression of VEGF-C is located in breast cancer cells,and VEGFR3,the receptors of VEGF-C is located in lymphatic vascular en- dothelial cells of tumor stroma tissue and peritumoral tissue.VEGF-C and VEGFR3 are closely correlated to the lymphangiogenesis and lymph node metastasis of breast cancer.